文献速递血栓与止血

以抗Xa因子导向的低分子肝素剂量降低遗传性抗凝血酶缺乏症孕妇静脉血栓栓塞风险

Anti-Xa directed low-molecular-weight heparin dosing to reduce the risk of venous thromboembolism in pregnant women with inherited antithrombin deficiency.
PubMed 文献 · J Thromb Haemost · 2025-08-08

本回顾性单中心队列研究纳入17名遗传性抗凝血酶缺乏症(ATD)孕妇的32次妊娠,评估本机构2012年改为抗Xa因子导向低分子肝素(LMWH)给药后的静脉血栓栓塞(VTE)发生率。共发生4例VTE(12.5%),其中3例与未达标剂量或依从性差相关;依从且接受抗Xa因子监测LMWH并围产期风险评估使用抗凝血酶浓缩物的孕妇无VTE发生。

要点

  • 32次妊娠中VTE发生4例(12.5%),其中2例为转诊前亚治疗剂量LMWH下发生。
  • 全队列LMWH起始剂量中位6250单位(96单位/kg),妊娠末期增至16750单位(247单位/kg)。
  • 20次妊娠围产期接受抗凝血酶浓缩物,产后出血4例(12.5%),1例轻度、3例中度。

核心结论

  • 在这项32次妊娠的回顾性队列中,12.5%发生VTE,但依从并接受抗Xa因子监测LMWH及围产期风险评估使用抗凝血酶浓缩物者无VTE发生。

研究设计与样本

  • 回顾性单中心队列研究,纳入17名遗传性抗凝血酶缺乏症孕妇的32次妊娠,从妊娠试验阳性随访至产后6周;12例为1型、5例为2型遗传性抗凝血酶缺乏症。

主要发现

  • 32次妊娠中22次(69%)活产,共发生4例VTE(12.5%):2例为转诊至本单位前使用亚治疗剂量LMWH时发生,1例为不依从的纯合AT Budapest患者,1例为不依从情况下的产后VTE。
  • 全队列LMWH起始剂量中位为6250单位(96单位/kg),至妊娠末期增至16750单位(247单位/kg)。
  • 20次妊娠围产期给予抗凝血酶浓缩物;产后出血4例(12.5%),其中1例轻度、3例中度。

临床怎么用

  • 本研究中心于2012年改为使用抗Xa因子导向的LMWH给药方案,并围产期风险评估使用抗凝血酶浓缩物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inherited antithrombin deficiency (ATD) is associated with a high risk of venous thromboembolism (VTE), particularly during risk periods, including pregnancy. Guidelines vary regarding thromboprophylaxis with low-molecular-weight heparin (LMWH). LMWH use in women with inherited ATD is hampered by the fact that antithrombin is the substrate for its anticoagulant effect, and therefore, larger doses of LMWH are needed. OBJECTIVES: Assess the rate of VTE in pregnant women with inherited ATD after our institution changed practice to using anti-Xa-guided LMWH in 2012. METHODS: This was a retrospective single-center cohort study of pregnant women with inherited ATD, followed from positive pregnancy test to 6 weeks postpartum. RESULTS: We identified 32 pregnancies in 17 women, 12 with type 1 and 5 with type 2 inherited ATD. Twenty-two (69%) resulted in a live birth. There were 4 cases of VTE (12.5%): 2 occurred in women prior to referral to our unit on subtherapeutic doses of LMWH; 1 in a nonadherent patient with homozygous AT Budapest; and 1 postpartum VTE in the setting of nonadherence. The median starting dose of LMWH in the whole cohort was 6250 units (96 units/kg), increasing to 16 750 units (247 units/kg) by the end of pregnancy. Antithrombin concentrate was given peripartum in 20 pregnancies. There were 4 postpartum hemorrhages (12.5%), 1 minor and 3 moderate. CONCLUSION: In this retrospective cohort study of 32 pregnancies, 12.5% of our cohort had a VTE. However, there was no VTE in those who were adherent and received anti-Xa monitored LMWH with risk-assessed use of peripartum antithrombin concentrate.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Dix C, Breen K, Robinson S, et al. Anti-Xa directed low-molecular-weight heparin dosing to reduce the risk of venous thromboembolism in pregnant women with inherited antithrombin deficiency. J Thromb Haemost. 2025. PMID: 40784553. doi:10.1016/j.jtha.2025.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。